AbbVie has reported interim results from the 156wks. P-III (Study 3101-312-002) extension trial assessing the long-term safety & tolerability of atogepant (60mg, oral) as a preventive treatment of migraine in patients (n=595) with chronic or episodic migraine
The trial involved patients from the P-III (PROGRESS & ELEVATE) studies who concluded the evaluations and had a baseline monthly migraine day burden of 14.5 days
The results demonstrated an improvement in monthly migraine days by an average of 8.5 days and a ≥50% reduction in monthly migraine days was observed in 70% of patients at wks.13-16, both of which sustained for over 48wks.
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie Receives the MHRA’s Marketing Authorisation of Aquipta (atogepant) for the Prevention of Migraines in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
